NCT00692341View on ClinicalTrials.gov

Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Hepatic Insufficiency
Interventions
DRUG

AG-013736

Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.

DRUG

AG-013736

Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.

DRUG

AG-013736

Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.

Trial Locations (2)

32809

Pfizer Investigational Site, Orlando

33169

Pfizer Investigational Site, Miami

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY